Study on the Extrapolability of Current Tumorgenicity Test With Mice by Comparing the Syngeneic or Allogeneic Mouse Transplantation Model

Takashi Tamura,Tsuyoshi Tahara,Michiko Inoue,Ryota Nanjo,Hirotaka Onoe,Takako Yamamoto,Shin Kawamata

DOI: https://doi.org/10.1093/stcltm/szae019

2024-03-30

Stem Cells Translational Medicine

Abstract:Abstract The extrapolability of the current tumorigenicity test performed by transplanting human cell product into immunodeficient (NOG) mice was investigated. For this purpose, the susceptibility to form teratomas of NOG mice was assessed by transplanting undifferentiated human-induced pluripotent stem cells (hiPSCs) as positive control cells via the liver, striatum, or tail vein and evaluating the TPD50 value (dose required to form teratomas in half of the transplanted mice). This was then compared to the TPD50 of syngeneic or allogeneic mouse models. The TPD50 of C57/BL/6(B6)-iPSC or 129/Ola(129)-embryonic stem cell (ESC) transplanted into the liver of syngeneic mice was 4.08 × 105 and 4.64 × 104 cells, respectively, while the TPD50 of hiPSC administered into the liver of NOG mice was 4.64 × 104 cells. The TPD50 of B6-miPSC-synergic, 129-mESC-synergic, or 129-cell/B6 allogeneic transplantation into the striatum was 5.09 × 102, 1.0 × 104, and 3.73 × 104 cells, respectively, while that of hiPSC/NOG mice was 1.0 × 103 cells. The TPD50 for B6-miPSC or 129-mESC syngeneic tail vein infusion was 3.16 × 106 or 5.62 × 106 cells, respectively, while no incidence was observed from 1 × 107 B6-miPSCs in 129 mice or hiPSCs in NOG mice infusion study. Although the number of data sets was limited, these data indicate that the teratoma formation from transplanted undifferentiated hiPSCs via the liver or striatum in NOG mice is comparable to that in syngeneic or allogeneic mouse transplantation model, suggesting that the result of the current tumorigenicity test in NOG mice would provide useful information to infer the incidence of teratoma from residual undifferentiated hPSCs in hPSC-derived products after transplantation.

cell & tissue engineering

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the extrapolation of current tumorigenicity testing by transplanting human - induced pluripotent stem cells (hiPSC) in immunodeficient (NOG) mice. Specifically, the study evaluates whether the NOG mouse model can reliably predict clinical outcomes, especially the safety of using hiPSC - derived products in the first - in - human (FIH) trials, by comparing the results of tumorigenicity tests in syngeneic or allogeneic mouse transplantation models.

### Research Background
Pluripotent stem cell (PSC) - based cell therapies show great potential in treating a variety of diseases, such as Parkinson's disease, chronic heart failure, age - related macular degeneration, etc. However, the final PSC - derived products may sometimes contain incompletely differentiated cells, which have the potential risk of forming non - target tissues (including tumors or teratomas). Therefore, tumorigenicity testing is required before clinical application to evaluate the safety of these undifferentiated cells.

### Research Objectives
1. **Evaluate the extrapolation of the NOG mouse model**: Evaluate the reliability of the NOG mouse model in predicting clinical tumorigenicity by comparing the results of tumorigenicity tests in different transplantation models (syngeneic, allogeneic, xenotransplantation).
2. **Determine the tumorigenicity of different transplantation routes**: Evaluate the differences in tumorigenicity of different routes by calculating the TPD50 values (the dose required to form teratomas in half of the transplanted mice) of different transplantation routes (liver, striatum of the brain, tail vein injection).

### Methods
- **Cell lines**: miPSC derived from C57BL/6 mice, mESC derived from 129/Ola mice, and human - induced pluripotent stem cells (hiPSC) were used.
- **Cell labeling**: Cells were genetically labeled by transfecting the luciferase gene (FlucIP) to improve the detection sensitivity of small cell clusters in deep organs.
- **Transplantation experiments**: Different doses of undifferentiated cells were injected into mice through the liver, striatum of the brain, or tail vein, and the formation of teratomas was monitored by the IVIS imaging system.
- **Data analysis**: The TPD50 values were calculated using the Spearman - Kärber method.

### Results
- **Liver transplantation**:
- Syngeneic transplantation (miPSC - B6): TPD50 = \(4.08\times10^{5}\) cells
- Syngeneic transplantation (mESC - 129): TPD50 = \(4.64\times10^{4}\) cells
- Xenotransplantation (hiPSC - PFX#9): TPD50 = \(4.64\times10^{4}\) cells

- **Striatum of the brain transplantation**:
- Syngeneic transplantation (miPSC - B6): TPD50 = \(5.09\times10^{2}\) cells
- Syngeneic transplantation (mESC - 129): TPD50 = \(1.0\times10^{4}\) cells
- Allogeneic transplantation (mESC - 129 to B6 mice): TPD50 = \(3.73\times10^{4}\) cells
- Xenotransplantation (hiPSC - PFX#9): TPD50 = \(1.0\times10^{3}\) cells

- **Tail vein injection**:
- Syngeneic transplantation (miPSC - B6): TPD50 = \(3.16\times10^{6}\) cells
- Syngeneic transplantation (mESC - 129): TPD50 = \(5.62\times10^{6}\) cells
- Allogeneic transplantation (mESC - 129 to B6 mice): No teratoma formation
- Xenotransplantation (hiPSC - PFX#9): No teratoma formation

### Conclusions
The research results show that the NOG mouse model has a certain reliability in predicting the tumorigenicity after transplantation of hiPSC - derived products. Although there are differences in TPD50 values among different transplantation routes and models, in general, the results of the NOG mouse model are comparable to those of the syngeneic or allogeneic mouse models, which provides useful information for evaluating the safety of hiPSC - derived products.